Streetwise Reports' Article Archives — January 2021 back to current month (31)

Novavax Shares Shoot 65% Higher on Phase 3 COVID-19 Vaccine Trial's 89.3% Effectiveness (01/29/2021)

Novavax Inc. shares established a new 52-week high after the firm's COVID-19 vaccine demonstrated an 89.3% efficacy rate in a Phase 3 trial in the U.K. and also showed efficacy against the South African variant in a Phase 2b trial.


Abiomed Shares Gain 8% After Firm Announces Record Q3 Revenue of $232 Million (01/28/2021)

Shares of cardiac medical device maker Abiomed Inc. traded higher after the company reported record revenue for Q3/21 despite the impact from COVID-19.


Coverage Initiated on Biotech 'Improving Drugs Via Prodrug' (01/27/2021)

KemPharm's key near-term catalyst, lead value driver and other pipeline drug candidates are discussed in a ROTH Capital Partners report.


Life Sciences Co. Receives Large Livestock Feed Order from New Client in Mexico (01/27/2021)

Avivagen Inc. reported it has secured a six tonne order for OxC-beta™ Livestock from a new customer in Queretaro City, Mexico.


Sorrento Shares Rise 35% After Firm Posts Positive Data from Phase 1b ICU COVID-19 Trial (01/27/2021)

Shares of Sorrento Therapeutics traded higher after the company released positive preliminary results from it of Phase 1b COVI-MSC™ Study for treatment of hospitalized ICU COVID-19 patients.


Vir Shares Climb 48% on Initial Phase 1 Chronic Hepatitis B Trial Data (01/26/2021)

Vir Biotechnology shares traded higher after the company reported data from its Phase 1 Chronic Hepatitis B Study that showed VIR-3434 significantly and rapidly reduced hepatitis B surface antigen.


Telemedicine Firm Partners to Offer Reliq Health's iUGO Care RPM and CCM Platforms (01/25/2021)

iDocsWeb reported it formed a strategic partnership with Reliq Health Technologies to offer that firm's iUGO Remote Patient Monitoring, Chronic Care Management and Behavioral Health solutions platforms to its U.S. customers.


Aurinia Pharma Shares Open at 52-Week High as FDA Approves Adult Lupus Nephritis Drug (01/25/2021)

Shares of Aurinia Pharmaceuticals traded 30% higher after the company reported that the U.S. Food and Drug Administration approved its LUPKYNIS™ (voclosporin) for use in treating adults with active lupus nephritis.


AzurRx Doses First Two People in Expanded Phase 2b Trial of Cystic Fibrosis Patients (01/22/2021)

AzurRx BioPharma shares traded 45% higher after the firm advised it had dosed the first two patients in its Phase 2b OPTION 2 Extension Study of MS1819 for treatment of exocrine pancreatic insufficiency in patients with cystic fibrosis.


Healthcare Tech Firm Announces New Multilingual IVR Product (01/21/2021)

Reliq Health Technologies launched a multilingual interactive voice recognition product called iUGO Care IVR and has contracted with a Maryland physician practice to offer the service to patients speaking Russian and English.


Imagin Medical Is Bringing Cystoscopy into the 21st Century (01/21/2021)

Dr. KSS, MD, PhD, editor-in-chief of, profiles a small cap that "is poised to bring to clinic a next-generation of must-have cystoscopy equipment."


Biotech Given Go-Ahead to Proceed with Phase 3 COVID-19 Study (01/20/2021)

Algernon Pharmaceuticals reported that it has been granted approval from the Data and Safety Monitoring Board to conduct a Phase 3 Study of Ifenprodil for SARS-CoV-2.


Gritstone Oncology Licenses LNP Platform from Genevant Sciences to Develop COVID-19 Vaccine (01/20/2021)

Shares of Gritstone Oncology reached a new 52-week high price after the company advised it entered into a non-exclusive licensing agreement with Genevant Sciences to develop and commercialize self-amplifying RNA vaccines for use against SARS-CoV-2.


Life Sciences Firm Partners with University to Develop Biosynthetic Psilocybin (01/19/2021)

Revive Therapeutics entered into a research agreement with North Carolina State University to develop psilocybin utilizing a natural biosynthesis enzymatic platform.


Aclaris Shares Triple in Value on Positive Topline Data from Phase 2a Rheumatoid Arthritis Trial (01/19/2021)

Shares of Aclaris Therapeutics Inc. soared to a new 52-week high after the company reported positive preliminary topline data from its Phase 2a trial of oral ATI-450 for moderate to severe rheumatoid arthritis.


Neurosciences Firm Outlines Strategic Priorities for 2021 (01/15/2021)

ProMIS Neurosciences discusses its four priority areas in 2021.


Avinger Shares Rise 40% on Launch of Image-Guided Device to Diagnose and Treat PAD (01/15/2021)

Shares of Avinger Inc. reached a new 52-week high after the company reported it initiated a full commercial launch of its Tigereye™ Image-Guided CTO Crossing Catheter system for diagnosing and treating peripheral artery disease.


As Psychedelics Move Mainstream, Small Cap Positions Itself at the Center of the Industry (01/13/2021)

Two year old DELIC Corp. has gotten in on the ground floor of the nascent psychedelic sector.


Inari Shares Flow 14% Higher on Triple Digit YoY Growth in Procedures and Revenues (01/13/2021)

Shares of Inari Medical Inc. established a new 52-week high after the company reported that preliminary revenue in Q4/20 increased year-over-year by greater than 140%.


Mesoblast Reports Phase 3 Trial Data Showing Substantial Reductions in Cardiac and Stroke Events in CHF Patients (01/11/2021)

Shares of Mesoblast Ltd. traded 36% higher after the company reported positive results from its Phase 3 DREAM-HF study showing that a single dose of rexlemestrocel-L provided very significant decreases in heart attacks, strokes and cardiac death in patients diagnosed with chronic heart failure.


A Novel, First-in-Class Blood Clotting Agent Takes Shape as a Bloody Compelling Investment (01/11/2021)

Private start-up RxMP's safe way to stop bleeding inexpensively is already the envy of bigger players, states Dr. KSS, MD, PhD, editor-in-chief of Can it go the distance through proof of concept?


Pharma Developer Outlines 2021 Clinical Program Initiatives (01/08/2021)

Algernon Pharmaceuticals provided an update detailing its plans for 2021 clinical trials.


Chimerix Expands Late-Stage Oncology Pipeline Through $78M Oncoceutics Acquisition (01/08/2021)

Chimerix Inc. shares traded 65% higher after the company reported it entered into an agreement to acquire Oncoceutics Inc. in a combination stock and cash deal valued at $78 million plus milestone incentives totaling up to $360 million.


Small-Cap Tech Stock Sees Huge Rise; What's Next? (01/07/2021)

Technical analyst Clive Maund charts Leonovus and discusses what could lie ahead for the stock after it gained 150%.


Biopharma's Acute Migraine Trial Yields Positive Efficacy, Safety Results (01/06/2021)

The recently announced topline results from Axsome Therapeutics' MOVEMENT study are reviewed in a Ladenburg Thalmann report.


This Tiny Digital Healthcare Company's Sales Should Rocket Higher (01/06/2021)

Independent financial analyst Matt Badiali profiles a small cap whose blood glucose monitoring system works with any smartphone.


Change Healthcare Shares Surge 30% on $7.8B Merger with UNH's OptumInsight (01/06/2021)

Change Healthcare shares rose to a new 52-week high after the company reported it will be combining its operations with UnitedHealth's OptumInsight in an all cash purchase transaction for $25.75 per share.


This Tiny Tech Stock Is Quietly Building a Huge Business in Air Quality (01/05/2021)

Independent financial analyst Matt Badiali discusses how mCloud's technology is making it possible for office buildings to reopen during the pandemic.


Biopharma Recaps 2020 Accomplishments in COVID-19, Idiopathic Pulmonary Disease (01/04/2021)

Algernon Pharmaceuticals reports that it is aggressively advancing its repurposed drug, Ifenprodil.


Biopharma Appoints Adviser for Phase 3 COVID-19 Trial (01/04/2021)

Revive Therapeutics selects Dr. John Fahy, California-based pulmonary medicine expert and researcher, to join its team.


Pandion Shares Get a Lift from Positive Top-Line Data in Phase 1a Autoimmune Disease Trial (01/04/2021)

Pandion Therapeutics shares traded 35% higher after the company reported positive top-line data from its Phase 1a clinical study of PT101 for treating autoimmune diseases including ulcerative colitis and systemic lupus erythematosus.


More Archives

2024Jun May Apr Mar Feb Jan

2023Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2022Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2021Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2020Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

2019Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Notable Quotes